Page last updated: 2024-11-03

pyridinolcarbamate and Infections, Respiratory

pyridinolcarbamate has been researched along with Infections, Respiratory in 1 studies

Pyridinolcarbamate: A drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1408)

Research Excerpts

ExcerptRelevanceReference
"The global burden of lower respiratory infections (LRIs) and corresponding risk factors in children older than 5 years and adults has not been studied as comprehensively as it has been in children younger than 5 years."1.72Age-sex differences in the global burden of lower respiratory infections and risk factors, 1990-2019: results from the Global Burden of Disease Study 2019. ( , 2022)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies

Other Studies

1 other study available for pyridinolcarbamate and Infections, Respiratory

ArticleYear
Age-sex differences in the global burden of lower respiratory infections and risk factors, 1990-2019: results from the Global Burden of Disease Study 2019.
    The Lancet. Infectious diseases, 2022, Volume: 22, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Bayes Theorem; Child; Child, Preschool; Female; Global Burden of Dis

2022